Adaptive Biotechnologies Corporation (ADPT)
ADPT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$25.28
-1.13% on the day
Market cap
$4.0B
Mid cap
Revenue · 2025
$277.0M
+54.8% on 2024
Net income · 2025
-$59.5M
-21.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ADPT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001478320 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | WA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $277.0M |
| Net income | -$59.5M |
| Operating income | -$57.1M |
| Net margin | -21.5% |
| Operating margin | -20.6% |
| Revenue growth | +54.8% |
| Cash | $70.5M |
| Total assets | $512.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 14.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2020-08-21 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-07-29 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 825 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.3% |
| 1 month | -3.8% |
| 3 months | +16.2% |
| Year to date | +58.1% |
| 1 year | +65.6% |
| From 52-week high | -14.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLAY | Relay Therapeutics Inc. | $17.36 | -3.45% | $3.8B |
| CRSP | CRISPR Therapeutics AG Common Shares | $50.10 | -2.81% | $4.8B |
| TARS | Tarsus Pharmaceuticals Inc. | $70.82 | -4.81% | $3.3B |
| SRRK | Scholar Rock Holding Corporation | $40.52 | -3.39% | $4.9B |
| CGON | CG Oncology Inc. | $62.40 | -1.16% | $5.5B |
| DNLI | Denali Therapeutics Inc. | $18.40 | -2.90% | $2.9B |
| KOD | Kodiak Sciences Inc | $91.63 | -7.69% | $5.8B |
| IMVT | Immunovant Inc. | $28.71 | -2.61% | $5.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier